

- **Name:** Ronan Joseph Kelly
 - **Current Position & Affiliation:** Director of Oncology at The Charles A. Sammons Cancer Center and the W.W. Caruth Jr. Endowed Chair of Immunology at Baylor University Medical Center Dallas Texas
Chief of Oncology Baylor Scott & White Health Care System (NTX)
 - **Country:** USA
-

- **Educational Background:**

Dr. Kelly received his medical degree from the Royal College of Surgeons in Ireland in 1998. He completed his internship, residency and oncology fellowship from the Royal College of Physicians in Ireland in 2007. Dr. Kelly completed a second fellowship in medical oncology at the National Cancer Institute (NCI) in Bethesda MD from 2007–2009 and continued as a clinical researcher in thoracic oncology at the NCI until moving to Johns Hopkins in 2011.

- **Professional Experience:**

Dr. Ronan Kelly, M.B., B.Ch., M.B.A is the Director of the Charles A. Sammons Cancer Center and the W.W. Caruth Jr. Endowed Chair of Immunology at Baylor University Medical Center in Dallas Texas and the Chief of Oncology for the Baylor Scott & White Health System (NTx).

Dr. Kelly is a Clinical Professor at Texas A&M University and Professor Clinical Science Division at the Translational Genomics Research Institute (TGEN). He remains an Adjunct Associate Professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He previously served as the Director of the Gastroesophageal Cancer Therapeutics Program at Johns Hopkins and as the Director of Global Oncology for John Hopkins International.

- **Professional Organizations:**

Dr Kelly is the Founder and the Director of the Texas Immuno-Oncology Biorepository which is providing comprehensive, standardized and cutting-edge immune monitoring across thousands of real-world cancer patients throughout Texas to enhance cancer therapy and improve biomarker discovery across a diverse community from multiple racial, genomic and social backgrounds. Dr Kelly is also the Founder and the Director of the Texas Multi-Cancer Early Detection (MCED) Registry which is investigating the impact of utilizing a novel ctDNA assay as a pan cancer screening test across a primary care population in patients aged 50 to 80 years old. He is the Chair of the International Association for the Study of Lung Cancer (IASLC) Quality and Value Taskforce which is seeking to improve the quality of lung cancer care across the World and he sits on the ASCO Measures Taskforce (lung cancer chair), Quality of Cancer Care Taskforce, International Quality Taskforce and the Clinical Practice Committee. He is currently leading a new initiative between ASCO and the IASLC to improve lung cancer care in Brazil and Spain. He is a taskforce member of the Gastroesophageal Cancer Committee of ECOG and the National Cancer Institute. Dr Kelly is author or co-author of more than 150 publications, including peer-reviewed journal articles, abstracts and book chapters.

- **Main Scientific Publications:**

He is the National and International Principal Investigator on numerous ongoing phase II and phase III studies investigating single agent and combination checkpoint inhibitors in locally advanced and metastatic gastroesophageal cancer. Dr Kelly was the lead investigator and first author for the practice changing Phase III global CheckMate 577 study across 29 countries and 170 sites, which demonstrated the efficacy of adjuvant Nivolumab in resected stage II/III esophageal/gastroesophageal cancer post trimodality therapy. The results of the CheckMate 577 study were published in the New England Journal of Medicine in April 2021.